Soleno beats Q4 ests with non-GAAP EPS $0.80 (+163% YoY), revenue $91.7M on rapid VYKAT XR launch
Soleno Therapeutics beats Q4 estimates with non-GAAP EPS $0.80 (+163% YoY) and revenue $91.7M on rapid VYKAT XR launch
- Q4 2025 revenue grew ~40% sequentially, reflecting strong ongoing momentum from the VYKAT XR launch.
- FY 2025 net income was $20.9M as Soleno achieved full-year profitability within nine months of first sales.
- VYKAT XR has penetrated ~12.5% of the U.S. addressable PWS market, with patient adherence described as high.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.